Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hanmei Lou, Shuxia Cheng, Yun Yan Zhang, Shihai Liao, Hui Li, Xinrao Wu, Jieqing Zhang, Huaming Lin, Yuzhi Li, Huan Zhou, Qin Xu, Haihua Yang, Hui Zhang, Linsheng He, Bingzhong Zhang, Xin Huang, Jason Jisheng Wu
Institutions: Zhejiang Cancer Hospital, Henan Cancer Hospital, Harbin Medical University, Guangdong Medical College, The First People's Hospital of Changde, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, First Affiliated Hospital of Bengbu Medical College, Fujian Provincial Cancer Hospital, Fourth Hospital of Hebei Medical University, Jiangxi Maternal and Child Health Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410812249